Illumina Inc
NASDAQ:ILMN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
98.2977
155.15
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ILMN stock under the Base Case scenario is 141.3 USD. Compared to the current market price of 141.09 USD, Illumina Inc is Fairly Valued.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Illumina Inc
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
Historical valuation for ILMN cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Illumina Inc
Balance Sheet Decomposition
Illumina Inc
Current Assets | 2.4B |
Cash & Short-Term Investments | 939m |
Receivables | 715m |
Other Current Assets | 719m |
Non-Current Assets | 3.6B |
Long-Term Investments | 218m |
PP&E | 1.3B |
Intangibles | 1.4B |
Other Non-Current Assets | 720m |
Current Liabilities | 975m |
Accounts Payable | 191m |
Accrued Liabilities | 422m |
Other Current Liabilities | 362m |
Non-Current Liabilities | 2.9B |
Long-Term Debt | 2B |
Other Non-Current Liabilities | 926m |
Earnings Waterfall
Illumina Inc
Revenue
|
4.4B
USD
|
Cost of Revenue
|
-1.6B
USD
|
Gross Profit
|
2.8B
USD
|
Operating Expenses
|
-2.5B
USD
|
Operating Income
|
344m
USD
|
Other Expenses
|
-1.9B
USD
|
Net Income
|
-1.6B
USD
|
Free Cash Flow Analysis
Illumina Inc
USD | |
Free Cash Flow | USD |
ILMN Profitability Score
Profitability Due Diligence
Illumina Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Illumina Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
ILMN Solvency Score
Solvency Due Diligence
Illumina Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Illumina Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ILMN Price Targets Summary
Illumina Inc
According to Wall Street analysts, the average 1-year price target for ILMN is 167.19 USD with a low forecast of 121.2 USD and a high forecast of 266.7 USD.
Dividends
Current shareholder yield for ILMN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ILMN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 9,800 full-time employees. The company went IPO on 2000-06-28. The firm operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The firm's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one ILMN stock under the Base Case scenario is 141.3 USD.
Compared to the current market price of 141.09 USD, Illumina Inc is Fairly Valued.